{"id":51464,"date":"2022-12-01T16:02:32","date_gmt":"2022-12-01T15:02:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/"},"modified":"2022-12-01T16:02:32","modified_gmt":"2022-12-01T15:02:32","slug":"ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/","title":{"rendered":"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit"},"content":{"rendered":"
\n

WALTHAM, Mass. & MONTREAL–(BUSINESS WIRE)–Ventus Therapeutics, Inc.<\/a>, a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, <\/b>announced that its Head of In Vitro and In Vivo Pharmacology, Anick Auger, presented an overview of the company\u2019s novel NLRP3 inhibitor programs at the Fourth Inflammasome Therapeutics Summit, held from Nov. 29 to Dec. 1 in Boston.\n<\/p>\n

<\/a><\/p>\n

\nMs. Auger detailed Ventus\u2019 unique approach to structure-based drug discovery, which allowed the company to quickly identify and progress structurally distinct NLRP3 inhibitors and build a library of these potent inhibitors with pharmacological diversity. She also provided an update on the company\u2019s brain-penetrant NLRP3 inhibitor, VENT-02, which was recently selected as Ventus\u2019 second development candidate. VENT-02 has demonstrated potent inhibition of NLRP3 activity in peripheral blood mononuclear cells and whole blood across species. VENT-02 also showed an excellent CNS-to-plasma exposure ratio in all preclinical species, as well as robust in vivo<\/i> activity.\n<\/p>\n

\n\u201cVENT-02 has demonstrated strong potential thus far in its development. As Ventus\u2019 second NLRP3 development candidate, it shows our belief in targeting this inflammasome to address systemic and neurological diseases,\u201d said Ms. Auger. \u201cWe are eager to progress our novel NLRP3 inhibitors towards the clinic and anticipate initiating a Phase 1 clinical trial for VENT-02 in 2023.\u201d\n<\/p>\n

\nFor more information on the Inflammasome Therapeutics Summit, visit: https:\/\/inflammasome-therapeutics.com\/<\/a>.\n<\/p>\n

\nAbout NLRP3<\/b>\n<\/p>\n

\nNLRP3 is a member of a family of proteins known as inflammasome receptors and is integral in the formation of the NLRP3 inflammasome. Inflammasomes are multiprotein complexes that regulate the innate immune system and are involved in intracellular surveillance of danger signals that trigger an intense inflammatory response, via generation of IL-1\u03b2, IL-18 and lytic cell death termed as pyroptosis. Therapeutic inhibition of NLRP3 can, therefore, prevent the formation of the NLRP3 inflammasome, which in turn inhibits the production of IL-1\u03b2 and IL-18. Aberrant activation of the NLRP3 inflammasome has been associated with systemic conditions, including fibrotic, dermatological, and rheumatological diseases, and figures prominently in several neurological disorders, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and multiple sclerosis.\n<\/p>\n

\nAbout Ventus Therapeutics<\/b>\n<\/p>\n

\nVentus Therapeutics is a biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets, with an initial focus on immunology, inflammation and neurology. The Company\u2019s proprietary drug discovery platform ReSOLVE gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic blueprints that can guide the development of differentiated small molecule medicines. The Company\u2019s lead programs target key innate immune modulators, including NLRP3 and cGAS. The Company aims to use its ReSOLVE platform to improve the way medicines are discovered and developed, with the ultimate goal of restoring the health of people facing serious illnesses. For more information, please visit www.ventustx.com<\/a> and engage with Ventus on Twitter @Ventus_Tx<\/a> or on LinkedIn<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/strong>\n<\/p>\n

\nThis press release contains forward-looking statements about future expectations, plans and prospects, including, but not limited to, statements related to the anticipated benefits of the executive leadership team, Ventus\u2019 business strategy, current programs, future results of operations, and financial position. These forward-looking statements are based on the Company\u2019s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the timing, progress, and results of preclinical and clinical studies involving its development programs; the results of its earlier studies not being predictive of future results; its ability to enhance the ReSOLVE platform; its ability to continue to obtain funding for its operations and to implement its business strategy; the impact of the COVID-19 pandemic on its business and its efforts to address the impact on its business; anticipated developments related to its competitors and its industry; the performance of third-party service providers, including suppliers and manufacturers; and its ability to obtain, maintain, and protect its intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ventus undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or otherwise.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Kyle Evans
\n
ICR Westwicke
\n
646-277-1295
\n
Kyle.evans@westwicke.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass. & MONTREAL–(BUSINESS WIRE)–Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, announced that its Head of In Vitro and In Vivo Pharmacology, Anick Auger, presented an overview of the company\u2019s novel NLRP3 inhibitor programs … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51464","6":"format-standard","7":"category-industry"},"yoast_head":"\nVentus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass. & MONTREAL–(BUSINESS WIRE)–Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, announced that its Head of In Vitro and In Vivo Pharmacology, Anick Auger, presented an overview of the company\u2019s novel NLRP3 inhibitor programs ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-01T15:02:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221201005097\/en\/1651412\/21\/High_Res_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit\",\"datePublished\":\"2022-12-01T15:02:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/\"},\"wordCount\":736,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221201005097\\\/en\\\/1651412\\\/21\\\/High_Res_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/\",\"name\":\"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221201005097\\\/en\\\/1651412\\\/21\\\/High_Res_Logo.jpg\",\"datePublished\":\"2022-12-01T15:02:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221201005097\\\/en\\\/1651412\\\/21\\\/High_Res_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221201005097\\\/en\\\/1651412\\\/21\\\/High_Res_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/","og_locale":"en_US","og_type":"article","og_title":"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit - Pharma Trend","og_description":"WALTHAM, Mass. & MONTREAL–(BUSINESS WIRE)–Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, announced that its Head of In Vitro and In Vivo Pharmacology, Anick Auger, presented an overview of the company\u2019s novel NLRP3 inhibitor programs ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-01T15:02:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221201005097\/en\/1651412\/21\/High_Res_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit","datePublished":"2022-12-01T15:02:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/"},"wordCount":736,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221201005097\/en\/1651412\/21\/High_Res_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/","url":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/","name":"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221201005097\/en\/1651412\/21\/High_Res_Logo.jpg","datePublished":"2022-12-01T15:02:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221201005097\/en\/1651412\/21\/High_Res_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221201005097\/en\/1651412\/21\/High_Res_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ventus-therapeutics-presents-an-overview-of-its-nlrp3-inhibitors-at-inflammasome-therapeutics-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51464"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51464\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}